Hormone therapy is the primary modality in the management of hypogonadism, but the variety of signs and symptoms makes early diagnosis challenging, and administering therapy involves numerous considerations influenced by various patient factors and the potential for adverse effects.
Key Findings
Background
Hypogonadism is classified into primary and secondary types, each caused by congenital and acquired factors.
Primary hypogonadism originates from testicular dysfunction; secondary hypogonadism originates from hypothalamic or pituitary dysfunction.
Contributing factors include genetic and developmental disorders, infection, kidney disease, liver disease, autoimmune disorders, chemotherapy, radiation, surgery, and trauma.
The multiplicity of etiological factors represents a considerable challenge in diagnosing hypogonadism.
Background
The goals of hypogonadism treatment encompass multiple physiological and functional outcomes.
Treatment goals include restoring sexual functionality and well-being.
Additional goals include initiating and sustaining virilization and osteoporosis prevention.
Goals also include normalizing growth hormone levels in elderly men if possible and restoring fertility in instances of hypogonadotropic hypogonadism.
Background
Hormone replacement therapy is the main treatment approach for hypogonadism but has specific contraindications.
Males with prostate cancer, breast cancer, and untreated prolactinoma are contraindicated for hormone replacement therapy.
Selection of testosterone therapy type requires consideration of the diversity of treatment response and the type of testosterone formulation.
Duration of therapy depends on individual response, therapeutic goals, signs and symptoms, and hormonal levels.
Background
The Endocrine Society Clinical Practice Guideline specifies therapeutic testosterone level targets and monitoring parameters.
Therapeutic goals are based on the alleviation of symptoms and signs.
Target testosterone levels are between 400–700 ng/dL, measured one week after administering testosterone enanthate or cypionate.
Maintaining baseline hematocrit is also specified as a therapeutic goal.
Response to testosterone therapy is evaluated based on symptoms and signs as well as improvements in hormone profiles in the blood.
Conclusions
Early diagnosis of hypogonadism is challenging due to the variety of presenting signs and symptoms.
The variety of signs and symptoms makes early diagnosis of this condition challenging.
Administering hypogonadism therapy involves numerous considerations influenced by various patient factors and the potential for adverse effects.
These factors pose a challenge for physicians to provide targeted hypogonadism therapy with minimal complications.